Limited Submission Funding Opportunities – updated 5/31/19

Please be aware that any grant that brings in less than 15% in indirect costs (IDC) will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

For MGH investigators selected through a competitive process as the institutional nominee for any limited submission funding opportunities, in situations in which the grant will bring in less than 15% indirect cost (IDC), ECOR will cover the IDC gap up to a maximum of $50,000 per year. In order to optimize the distribution of limited ECOR funds across the MGH research community, it is expected that PIs and departments will work together to cover the remaining IDC shortfall.

This policy is only effective for those limited submission opportunities in which MGH is invited to submit its own nominee(s). This policy does not apply for those limited submission opportunities in which the MGH investigator must apply through HMS.

For further questions, please contact ECOR at ecor@mgh.harvard.edu

We ask that all MGH Investigators interested in applying for any limited submission award submit a Letter of Intent (see detailed instructions below) to the MGH Executive Committee on Research (ECOR) by the deadline indicated for each award to be considered to receive an institutional nomination.

Process
Submit a one- to two-page Letter of Intent (LOI) to the MGH Executive Committee on Research (ECOR) via email to ecor@mgh.harvard.edu. In addition to your LOI, please include an NIH Biosketch.

The letter of intent should include:
1. Name of the Principal Investigator with appropriate contact information
2. A descriptive title of the potential application
3. Brief description of the project
4. Brief description of why you specifically should be selected to receive institutional nomination for this award

In the event that there is more than one MGH investigator interested in applying for a limited submission award, the LOIs will be used to assess candidates and a review and selection process will take place.

If there is a limited submission funding opportunity you do not see listed below or you have any additional questions, please let us know at ecor@mgh.harvard.edu.

CURRENT OPPORTUNITIES

1. Breast Cancer Alliance Young Investigator Grant
https://breastcanceralliance.org/how-to-apply
MGH LOI Deadline: 6/11/19
Sponsor Deadline: 7/19/19

The mission of the Breast Cancer Alliance is to improve survival rates and quality of life for those impacted by breast cancer through better prevention, early detection, treatment and cure. To promote these goals, we invest in innovative research, breast surgery fellowships, regional education, dignified support and screening for the underserved. To encourage a commitment to breast cancer research, the Breast Cancer Alliance invites clinical doctors and research scientists whose primary focus is breast cancer research, and who are in the early stages of their career, to apply for funding for the Young Investigator Grant.
Limited Submission Funding Opportunities – updated 5/31/19

Applicants for the 2020 award must (i) have held a faculty position for no more than four years following completion of their training, as of February 1, 2020; (ii) have not been a principal investigator on an NIH R01 or equivalent national/international non-mentored award; and (iii) dedicate at least 50% of their work effort to research. This grant is intended to help advance the careers of young researchers who do not yet have their own major grant support. The grant provides salary support and project costs for a total of $125,000 (distributed over the two-year period). Administrative costs, which are included in the $125,000 award, must be limited to 8% of grant funds.

The research project must be directly related to the field of breast cancer. Areas of relevant research may include but are not limited to: diagnosis, etiology, immunology, genetics, therapies, prevention and clinical studies.

2. St. Baldrick’s Fellows
https://www.stbaldricks.org/file/website_content/see_the_impact/2020-SBF-Fellowship-Guidelines.pdf
MGH LOI Deadline: 6/12/19
Sponsor LOI Deadline: 7/12/19
Sponsor Deadline: 8/30/19

The St. Baldrick's Foundation funds years 3-5 of a pediatric oncology research fellowship with an opportunity for one additional year of funding. This mechanism is designed to support a Fellow's salary and benefits only. The St. Baldrick's Foundation encourages applications from institutions with fellowship programs that have not previously received St. Baldrick's funding for this grant mechanism.

Applicants should be Research Fellows and should hold an M.D. or D.O. degree by the date the grant becomes effective. Fellows must have completed at least two (2) years of fellowship training prior to becoming a St. Baldrick's Fellow.

3. The NIGMS Human Genetic Cell Repository (U42 – Clinical Trial Not Allowed)
MGH LOI Deadline: 6/19/19
NIH Deadline: 7/09/19

The purpose of this FOA is to support the NIGMS Human Genetic Cell Repository (HGCR). The repository will maintain the current collection of cell cultures and DNA samples and will acquire, characterize, and expand high-quality cell samples, and distribute cell lines and DNA isolated from them to qualified biomedical researchers.

4. Institutional Development Award (IDeA) Program Infrastructure for Clinical and Translational Research (IDeA-CTR) (U54 Clinical Trial Optional)
MGH LOI Deadline: 7/15/19
NIH LOI Deadline: 9/02/19
NIH Deadline: 10/02/19

The purpose of this Funding Opportunity Announcement (FOA) is to support the development of infrastructure and other resources required for the conduct of Clinical and Translational Research (CTR) in IDeA-eligible states. IDeA-CTR Centers are expected to provide added value to the biomedical research
Limited Submission Funding Opportunities – updated 5/31/19

efforts in the participating institutions through support of activities that cannot easily be provided through standard research grant awards. The proposed activities will provide the infrastructure and resources that will enhance the competitiveness of the investigators to obtain additional funding for clinical and translational research. Applicants must establish a statewide network of collaborating and partnering institutions/organizations. Other institutions/organizations outside the state may be included if forming a network of wider reach. Since only one award will be made per IDeA-eligible state, only one application should be submitted per state.

5. Gabrielle’s Angel Foundation
http://gabriellesangels.org/what-we-do/grant-info/
MGH LOI Deadline: 7/16/19
Sponsor Deadline: 8/16/19

For over two decades, Gabrielle’s Angel Foundation has provided significant financial support to some incredibly promising physician scientists, who are applying novel and state-of-the-art techniques to address fundamental problems in the genesis and treatment of blood related cancers. Since 1996, the Foundation has committed more than $35 million in grants to over 300 junior faculty members at the nation’s leading institutions. These grants continue to be a sign of excellence and represent support for many of the most exciting new scientific ideas in blood cancer research.

Gabrielle’s Angel Foundation remains committed to funding innovative, translational proposals and to supporting promising independent early-career investigators, rather than well-established, senior scientists. Projects will be funded for a three-year period at $75,000 per year (contingent on the submission of acceptable annual progress reports). Please note that the foundation only covers 10% of indirect costs.

Applicants should be MD and/or PhD Assistant Professors who have been in their current position for no longer than five years.

The Foundation seeks to support integrative research projects that explore evidence-based complementary interventions, optimize the manner in which mainstream care is delivered and improve the lives of those living with cancer, specifically the hematologic malignancies. The Foundation also seeks to support clinical trials and/or pre-clinical research which address reducing patients’ physical and emotional distress during or after cancer therapy. Proposals will be evaluated for creativity, originality and scientific rigor and those based on promising preliminary data will be favored.

MGH is invited to submit two applications - one in the conventional medical research category and one in the integrative medical research category. In your LOI for this funding opportunity, please clearly indicate which category you will be applying within.

For more information on eligibility and the application process, click here.

Click here to view the FAQ.
6. Conference for Early Stage HIV/AIDS Researchers Using Nonhuman Primate Models (R13 Clinical Trial Not Allowed)
MGH LOI Deadline: 7/30/19
NIH Deadline: 9/10/19

This Funding Opportunity Announcement (FOA) encourages Research Conference Grant (R13) applications to conduct an annual intensive workshop/conference/meeting that addresses the needs of early stage HIV/AIDS researchers utilizing nonhuman primates (NHPs) as they translate preclinical research from NHPs to human clinical trials. The objectives of the meeting(s) supported by this FOA are to provide these early stage HIV/AIDS researchers with guidance on conducting preclinical research to inform clinical trials on reducing the incidence of HIV/AIDS infection, including vaccine development and testing; developing next-generation HIV therapies, including potential cure therapies; treatment of HIV-associated coinfections, comorbidities and complications; and infection prevention strategies. In addition to guidance on translating results to clinical trials, the conference should target developing skills related to networking, grantsmanship, and goal/milestone-driven projects. Conference topics should also include other considerations such as statistical and host genetics considerations; methods to translate the results of NHP studies to clinical trials in humans; and how to develop new NHP research programs to better reflect clinical observations and findings in human HIV/AIDS patients.